These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 30446941)

  • 1. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry.
    Kusenda J; Fajtova M; Kovarikova A
    Neoplasma; 2014; 61(2):119-27. PubMed ID: 24299307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of Residual Disease in Acute Myeloid Leukemia.
    Vedula RS; Lindsley RC
    Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
    Paiva B; Vidriales MB; Sempere A; Tarín F; Colado E; Benavente C; Cedena MT; Sánchez J; Caballero-Velazquez T; Cordón L; Garces JJ; Simoes C; Martínez-Cuadrón D; Bernal T; Botella C; Grille S; Serrano J; Rodríguez-Medina C; Algarra L; Alonso-Domínguez JM; Amigo ML; Barrios M; García-Boyero R; Colorado M; Pérez-Oteyza J; Pérez-Encinas M; Costilla-Barriga L; Sayas MJ; Pérez O; González-Díaz M; Pérez-Simón JA; Martínez-López J; Sossa C; Orfao A; San Miguel JF; Sanz MÁ; Montesinos P;
    Leukemia; 2021 Aug; 35(8):2358-2370. PubMed ID: 33526859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities.
    Chen X; Wood BL
    Blood Rev; 2017 Mar; 31(2):63-75. PubMed ID: 27742133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.
    Buccisano F; Hourigan CS; Walter RB
    Curr Hematol Malig Rep; 2017 Dec; 12(6):547-556. PubMed ID: 29027628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
    Li SQ; Chen M; Huang XY; Wang H; Chang YJ
    Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
    Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
    Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
    Fossat C; Roussel M; Arnoux I; Asnafi V; Brouzes C; Garnache-Ottou F; Jacob MC; Kuhlein E; Macintyre-Davi E; Plesa A; Robillard N; Tkaczuk J; Ifrah N; Dombret H; Béné MC; Baruchel A; Garand R;
    Cytometry B Clin Cytom; 2015 Jan; 88(1):21-9. PubMed ID: 25363877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia.
    Ouyang J; Goswami M; Peng J; Zuo Z; Daver N; Borthakur G; Tang G; Medeiros LJ; Jorgensen JL; Ravandi F; Wang SA
    Am J Clin Pathol; 2016 Jun; 145(6):769-77. PubMed ID: 27298396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method.
    van der Linde R; Smith S; Brown DA; Sasson SC; Tegg E
    Pathology; 2023 Apr; 55(3):383-390. PubMed ID: 36725446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia.
    Pettersson L; Levéen P; Axler O; Dvorakova D; Juliusson G; Ehinger M
    Genes Chromosomes Cancer; 2016 Oct; 55(10):750-66. PubMed ID: 27191933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of measurable residual disease detection in AML in morphologic remission.
    Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
    Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.